Based on these observations, several pDC‐targeting drugs such as anti‐interferon‐α (anti‐IFN‐α) monoclonal antibody (mAb) and anti‐type I IFN receptor subunit‐1 (anti‐IFNAR1) mAb are being assessed in SLE in clinical trials and have shown promising outcomes.11, 12, 13. This evidence concerns the gene IFNA1 and systemic lupus erythematosus.